Insilico Medicine

Rounds and research, on one timeline

1. 2026-09-17
   Research

   Level 2 · Computed

   Insilico and collaborators publish a 17-task benchmark and specialist LLMs for aging biology

   Aging has no agreed definition, unlike cancer's crisp endpoints, so the benchmark's contribution is turning that ambiguity into 17 checkable tasks rather than one contested clock.

   Timeline entry →doi.org ↗

2. 2026-09-07
   Research

   Level 3 · Checked against existing evidence

   Insilico ran six proteomic aging clocks on blood from its rentosertib trial, and treated patients read biologically younger than placebo, most clearly at week four

   It is an attempt to read an aging endpoint out of a disease trial, which is the trial design Insilico is arguing for. But it is the sponsor's exploratory reanalysis of stored samples, with nine to eleven patients per arm at each time point and seven Insilico employees among the authors. The authors say proteomic clocks alone cannot separate slower aging from a treated disease, that they could only address this indirectly, and that doing it properly needs healthy volunteers. The readings did not move further between weeks four and twelve.

   Timeline entry →doi.org ↗

3. 2025-12-30IPO
   Round

   about HK$2.026B net≈ $260M

   For: late-stage clinical programmes, new generative AI models, automated labs and early discovery

   Toward the clinicModels and platformAutomated lab

   94,690,500 shares at HK$24.05. Net figure from the allotment announcement as relayed by Gelonghui; the over-allotment added about HK$324.5M net on 2026-01-16. Use of proceeds from The Paper's report of the May 2025 prospectus filing; the final prospectus was not read. The 15 cornerstone investors are from 36Kr's report at the offer launch, drawn from the prospectus (https://www.36kr.com/p/3600333723058178).

   Anchor · LillyAnchor · TencentAnchor · TemasekAnchor · OaktreeAnchor · SchrodersAnchor · UBSAnchor · ChinaAMCAnchor · China Pacific Insurance (CPIC)Anchor · Fullgoal Fund ManagementAnchor · Harvest Fund ManagementAnchor · Taikang LifeAnchor · E Fund ManagementAnchor · RTWAnchor · ExomeAnchor · Infini

   By this date the record held 1 research entry, highest level 5

   Announced by the company · c.m.163.com ↗On the timeline →

4. 2025-06-03
   Research

   Level 5 · Used in practice

   An AI-discovered drug reaches randomized Phase 2a evidence

   Once an AI-discovered molecule reaches controlled human trials, clinical safety and efficacy become more important evidence than the sophistication of the discovery model.

   Timeline entry →nature.com ↗

5. 2025-03-13Series E
   Round

   $110M

   For: AI models, automated lab, clinical validation of the lead IPF drug

   Models and platformAutomated labToward the clinic

   Last private round before the IPO.

   Lead · Value Partners Group private equity fund

   On the deal: Chuen Yan Leung (Partner, Value Partners Group private equity fund)

   Announced by the company · prnewswire.com ↗

6. 2022-08-10Series D (second close)
   Round

   $35M

   For: accelerate internal programmes and use its AI platform to find more new therapeutics

   Models and platform

   Brings Series D to $95M in aggregate.

   Lead · Prosperity7 (Aramco)

   Announced by the company · insilico.com ↗

7. 2022-06-06Series D
   Round

   $60M

   For: pipeline, Pharma.AI, robotic drug-discovery lab

   Models and platformAutomated lab

   No lead named; the founder invested personally.

   BHR PartnersWarburg Pincus ✓B Capital Group ✓Qiming Venture Partners ✓BOLD Capital PartnersPavilion CapitalAlex Zhavoronkov

   On the deal: Min Fang (Managing Director, Head of China Healthcare, Warburg Pincus)

   Announced by the company · prnewswire.com ↗

8. 2021-06-22Series C
   Round

   $255M

   For: take programs into human trials; start new programs

   Toward the clinic

   Lead · Warburg Pincus ✓Qiming Venture Partners ✓Lilly Asia VenturesOrbiMed ✓Deerfield ManagementSequoia Capital China ✓B Capital Group ✓Pavilion CapitalEight Roads VenturesSinovation Ventures ✓BOLD Capital PartnersFormic VenturesBaidu Ventures ✓CPEMirae Asset CapitalMaison CapitalLake Bleu CapitalPresident International Development CorporationSage Partners

   On the deal: Fred Hassan (Spoke for Warburg Pincus, Warburg Pincus); Min Fang (Managing Director, Warburg Pincus, joins the board)

   The investor's own page says · Warburg Pincus: Investment Year 2021 (Stage: Growth)

   Announced by the company · prnewswire.com ↗

9. 2019-09-10Series B
   Round

   $37M

   For: commercialise its generative chemistry and target identification technology, build a senior team with pharma experience, and develop its pipeline in cancer, fibrosis, NASH, immunology and CNS for partnering

   Commercial roll-outHiring

   The release names Qiming Venture Partners as the lead; F-Prime Capital and Eight Roads participated. Series A investors also joined, unnamed.

   Lead · Qiming Venture Partners ✓Eight Roads VenturesF-Prime Capital ✓Lilly Asia VenturesSinovation Ventures ✓Baidu Ventures ✓Pavilion CapitalBOLD Capital Partners

   On the deal: Nisa Leung (Managing Partner, Qiming Venture Partners)

   Announced by the company · qimingvc.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →